Terumo Receives FDA Go-Ahead To Start Trial As Part Of U.S./Japan Pilot
This article was originally published in PharmAsia News
Japanese device maker Terumo on May 12 announced it had received conditional U.S. FDA approval to begin enrollment for a U.S. clinical trial of its Misago superficial femoral artery stent
You may also be interested in...
FDA and Japanese regulators recently began to work together to review two devices - one U.S.-manufactured, one Japanese-made - that are part of a new pilot program intended to model how products can achieve faster market entry in both countries
FDA and its Japanese counterpart will soon name the two devices - one American, one Japanese - they will use in a new pilot project that could lead to faster market access for products destined for both markets, according to CDRH's Carole Carey
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).